See something missing? Fill out this form to add your event.
Webinar #48 – Breaking Down Barriers in Rare Disease Research: Advantages and Obstacles in Data Sharing
- This event has passed.
February 24, 2022 @ 12:00 pm – 1:00 pm EST
Webinar Overview
This webinar includes three panelists, Deven McGraw, Charlene Son Rigby, and Dr. Jacob Donoghue, who dive into the importance of data sharing in rare disease research. Deven McGraw is the co-founder of Ciitizen, a company which works to put all of a patient’s health data into the hands of rare disease patients and families. Charlene Son Rigby is the CEO of Rare-X, a platform to gather, structure, and share patient-level data to support research and therapy development for rare disease patients. Finally, Dr. Jacob Donoghue is the CEO and co-founder of Beacon Biosignals, a platform for integrating brain data to support the development of novel precision medicines for neurologic and psychiatric disease. In this webinar, the panelists discuss the key barriers to rare disease research and what their companies are doing to remove them. These barriers include a lack of data for rare disorders, having trouble getting scientists interested in studying a rare disorder, and data access being competitive amongst scientists. However, their companies are combating these barriers by making advancements in data sharing – these advancements majorly shrink the time it takes for drug development or natural history studies. Throughout the webinar, all three panelists give incredible insights about rare disease research and data access which will shape the way data is shared in the future.
THIS IS A TRANSCRIPT ONLY:
0:04hello my name is Mike Graglia i am the founder managing director of the SynGAP Research Fund a
0:09rare disease group that I created for my son who suffers from a rare neurological disease called SYNGAP1 i’m excited to be with you today and to moderate this incredible panel because
0:19i know this is a topic that is very important i get phone calls often from other people creating
0:26rare disease groups struggling with this precise issue so this is a this is a timely and relevant
0:32panel that i’m excited to have recorded because i will be referring many people to hear these incredible experts let me introduce them to you now deven mcgraw jd llm
0:43three graduate degrees is the co-founder of Ciitizen which was acquired by Invitae last year and she is now the lead of data stewardship and data sharing for the Ciitizen platform at invite
0:53previously deven directed the u.s health privacy and security department as the deputy director
1:01health information privacy at HHS office for civil rights she was the acting chief privacy officer in
1:06the office national coordinator for health i.t Deven is widely recognized for her expertise in health privacy she directed the health privacy project at the center for democracy and technology
1:14for six years led the privacy and security policy for the high-tech committee she was also the chief
1:21operating officer at the national partnership for women and families she advised health industry clients on HIPAA compliance and data governance while a partner at manat phelps and phillips
1:30Devin graduated magna [ __ ] laude from georgetown and from her has her mph from jhu thank you so
1:37much for being with us demon Charlene son riggsby MBA is the chief executive officer of RARE-X she
1:44has spent her career building organizations at the intersection of data technology and life sciences
1:49Charlene was previously chief business officer at fabric genomics and held executive roles as enterprise software and genomics companies including oracle and doubletwist
1:57she started her career in neuroscience research at Roche when Charlene’s daughter was diagnosed
2:02with a rare genetic disease she co-founded the STXBP1 foundation she is committed to finding
2:08a cure for her daughter’s disorder Charlene’s unplanned connection between her personal life and profession has helped push forward the search for a cure for her daughter and kids like her
2:18and given her work deeper meaning she held an MBA in human biology from Stanford and a ba in human biology from Stanford and an MBA from the haas school at berkeley
2:29rounding out this star-studded panel jacob donahue MD PhD is the CEO and co-founder
2:35of Beacon biosignals a company that translates scientific innovation into clinical interventions
2:40he completed his MD from Harvard medical school and his PhD in neuroscience from MIT leading
2:46research into the effects of neuroactive compounds on brain network activity his published work spent
2:52epilepsy cognition and machine learning methods for quantifying pharmacological effects on neural
2:58activity so i think step one is to hear from these speakers they all spend their time running What is Citizen
3:08remarkable organizations and Deven if i could start with you could you please describe what
3:15your company the company you you now work with him now you’re part of invitae but the company helped
3:20create Ciitizen could you describe how it relates to this issue of data serving data sharing pardon
3:26me for rare disease research no sure happy to mike thanks for having me so citizen is a platform that
3:34helps patients or family members acting on their behalf to gather all their health information
3:41all of it from all the places where they’ve been seen and to put it under their control
3:47we were founded by anil sethi who lost his little sister to metastatic breast cancer
3:54and so we started in cancer but we we added rare neurological diseases in part
4:01through the advocacy of one of our key staff members whose child who has a child with FOXG1
4:08syndrome so we’ve been in the rare neurological disease space almost since our inception and
4:16and really you know the idea here is to put the power of data back into the hands of the people
4:22who are most likely to use it and to use it for good and that’s again the patients and family members acting on their behalf that’s it’s it’s kind of exciting we were you know being acquired
4:34by Invitae brings us into an organization that’s like-minded with respect to being dedicated to
4:39healthcare their genetic testing company for folks who don’t know them and so it’s really
4:45i hope will give us a lot more resources to scale versus you know trying to do all of
4:52this as a small company but again we really think that the answer to some of these data obstacles
4:57is put the data in the hands of patients and their families and we’ll and see what happens
5:04great thank you for that charlene can you tell us about rarex What is RareX
5:11thanks mike so rare x is a health tech non-profit and we’re also a patient advocacy organization
5:19we really started with the perspective of what do patients need to accelerate therapies and so
5:26patients really are at the center of how we’ve really developed our strategy and our approach
5:32and so what are we doing we’ve developed a platform to gather structure and share
5:39patient-level data to support the acceleration of research and therapy development for rare
5:44disease patients and this is really across the thousands of rare diseases and the growing
5:50number of rare diseases and i kind of specific to this discussion i wanted to highlight that a
6:01core principle of our approach is eliminating data silos so this includes upfront with our innovative
6:10consent process and also through enabling integration and federation with other data sources
6:19very nice you packed a lot in there i look forward to unpacking that as we go through this What is Beacon Biosignal
6:25jake can you tell us about beacon biosignals sure thanks mike yeah so beacon biosignals is a company building a machine learning platform
6:35for interrogating brain data at scale and to enable the development of novel precision measure
6:40medicines for neurologic and psychiatric disease really you know inspiration for for this uh
6:48this workers seeing the sort of developments that were occurring in companies working in
6:53digital pathology and thinking about how you know novel precision measurements can enable
6:59precision therapies especially in oncology and seeing firsthand taking care of patients
7:07just the limitations in the the way that data is collected and the inability to interpret the
7:12full depth and breadth of the brain data in this case EEG that there was an enormous opportunity
7:18to bring modern machine learning tools to understand this this critical data modality
7:23to enable these types of therapies to to be driven forward for patients with neurological psychiatric
7:29and sleep disorders nice i remember when i started syngap research fund somebody told me
7:36if you want to know what’s happening in what’s going to happen in rare neuroscience tomorrow
7:41look at what’s happening in cancer today because cancer’s so much bigger and so much better funded
7:46and you know it’s exactly what you just said and i think as devon alluded to citizen was started for cancer and then thank goodness they rolled into neurology so it’s it’s interesting to see
7:57that you’re you’re validating that all right so let’s let’s jump into our first question i think
8:04before we talk about breaking down the barriers it would be useful to name them right so what do you see as the key barriers to rare disease research and why is it necessary to remove them Barriers in Rare Disease Research
8:15jake let’s let’s stay with you for a second can you just talk you almost started to answer that already so can you just talk a little bit about the barriers that you see
8:23and and and uh and i don’t know if you want to talk more about beacon or just the barriers
8:30yeah in general i think so the key for us we’re you know data-driven company applying tools to
8:37better understand you know eeg you know brain data about in the patients with rare diseases
8:43rare genetic neurological diseases for beacon in particular the key to allowing these tools to be
8:50useful and provide actionable information is you actually have to have at least a reasonable amount
8:56of data and in rare disease where the number of you know eeg data may be hard to obtain
9:03for a number of reasons that limitation makes it really hard to actually identify patterns that
9:09could be critically useful to understanding which patients are going to benefit the most
9:15and then in early studies you know in phase one trials if a new treatment is actually having an effect so that limitation uh in the inability to acquire the data both at the site in the
9:26hospital settings or in community hospitals where there’s a limitation of eeg hardware and the fact that eeg data is often not part of the standard data types that can be requested
9:38from the hospitals if a patient asks for EEG their EEG data they often will be given
9:44a report of what was read on that data so all of that really important information about you know
9:51that child or that patient is really buried not only within the data but within this you know
9:56hospital system so i think that without access to these individual you know files no one is able to
10:02really interrogate sometimes the most important defining characteristics of disease got it so Barriers to Rare Disease Research
10:10low low n and then certain data types specifically EEG for neurology incredibly hard to move around
10:18charlene let me move to you what do you what do you see is the barriers to rare disease research
10:23yeah i think i can just really build on what jacob and you just described so you know giving a little
10:31bit of my personal perspective i also have a child as mike mentioned in my intro who has a rare
10:40neurodevelopmental disorder and she’s eight and she was diagnosed in 2016 so almost six years
10:47ago and we still have a long way to go before we get to a cure or even precision therapies with
10:54any wide access and there’s such painful urgency you know as parents and as advocates to you get
11:03to something that’s truly going to change the future for our kids and yet getting to this data
11:10that’s going to inform these therapies is difficult so you know mike you said small n i mean the n is small for any individual disorder and you know it’s even very very small
11:21for certain disorders and you know patients in these small in rare disease often have difficulty
11:29getting researchers interested in putting together a study to actually understand that disease
11:37and when they are successful those studies are you know they can find challenges in providing input
11:44into the study and then getting access to the data on the back end and as jacob mentioned oftentimes
11:51you know health care systems and studies they’re really generating silos of data and it’s very
11:56difficult to bring those data sets together and i think this is you know true broadly and you know
12:01the EEG example is you know just a a sore example of how you know this ends up becoming you know
12:10kind of a magnified problem and you know i think that this is due to a host of issues including
12:15data governance and misalignment of incentives and it’s very frustrating because especially in
12:23rare disease when we have this challenge of small numbers of patients we really need to maximize
12:29the utility of the data that we’ve gathered from these patient populations and you know
12:34it’s really data that these patients have contributed you know to hopefully accelerate
12:40the process toward therapies you know i really feel that this is a moral imperative
12:49you pack so much into your answers so there’s data governance issues there are data silos Data Governance Issues
12:55and then misaligned incentives and i just want to make sure i heard this correctly between researchers who are maybe doing it early on an industry who need to use that
13:03that data sometimes to actually get a real therapy through trials right did i am i putting words in
13:09your mouth or is that right yeah yes i think that’s right and then you know i’ll add in also the patients where you know it really needs to be you know having the patience
13:21around the table as true research partners and you know that’s uh you know unfortunately not the
13:28norm today right which is a great setup for deven but i also want to underscore one other thing you Barriers to Research
13:33said which was moral imperative so this isn’t an academic exercise right there are sick children
13:39and what stands between these sick children and therapies that exist in labs right now
13:44is the data and the data being used and shared between the players to make that happen so I love i’m going to bar i’m going to use that term liberally and occasionally give you credit we have
13:54a moral imperative to do this work devin what do you see as the barriers to rare disease research
14:02well i you know i agree with my co-panelists to me i think there’s two that sort of rise to the top
14:10one would be proprietary business interests right or or you know sort of lack of motivation to share
14:19or motivation not to share right with data is considered to be a competitive asset then you
14:24don’t want to share it with anybody similarly the the data governance rules are truly a challenge
14:30and this it that challenge gets particularly acute for rare because of the need to gather data across
14:37many jurisdictions in order to have a a meaningful data set if you’re just dealing with u.s patients
14:44and using the HIPAA right of access for example you’re you’re likely to to not have a sufficient
14:50amount of data to to power studies you need to be able to get data from patients who live in other
14:56countries and that means that you know they’ve got their you know data governance laws their privacy
15:02laws there are research laws that apply when you’re collecting data from patients overseas so
15:08that that does get challenging and i again i think that challenge becomes particularly acute and rare
15:13it’s interesting i i and i don’t think about removing these obstacles because some of them
15:19you’re not going to remove right you’re not going to you’re not going to you know sort of not have competitive instincts of companies of researchers you’re not gonna not have data governance laws
15:29that are gonna vary i consider it as doing an end run around them like what what are some of the
15:35the holes and the crevices that you can kind of crawl through and and figure this out and for and
15:41for us with the citizen platform it’s about you know every privacy law gives patients the right
15:47to a copy of their data and every privacy law allows patients and and or families acting on
15:55their behalf to direct that data to where it needs to go and when you pull on that thread
16:00you’ve got the possibility i think of creating that you know moving with some more urgency
16:06rather than waiting for the wheels to turn very slowly in all of these traditional models
16:12and hoping that that somebody agrees with you that it’s a moral imperative for us to act fast
16:21yes yes thousand times yes so it’s great so proprietary business interests are a reality HIPAA and Right of Access
16:29and we need to find that’s probably a whole other discussion how to navigate that and then
16:36the different jurisdictions i i take your point i mean i the group i lead SynGAP research fund does work with citizen i’m very proud of that and and
16:47consider myself very lucky and have lived through exactly what you’ve said right we’ve enrolled more
16:52than half of our us population but getting people from certain other countries is tricky and that’s
16:58that’s that’s difficult deven in your introduction which was so dense i might have mangled parts
17:05of it but can you just talk a little bit about HIPAA and patient right of access because I just
17:11i do think that that is at the heart of some of the genius of what you do at citizen and as you
17:17just alluded to one of the ways that we’re going to do an end run around some of these challenges
17:22yeah so i the under hipaa which is the the hipaa regulations are
17:29privacy laws that apply to most of them significant holders of clinical data clinical and claims data health healthcare facilities doctors hospitals labs
17:44and uh and also to the companies that work with them health plans as well the there’s
17:50no mandate to share data under hipaa except for two one is with the government when you’re being
17:56investigated i used that a lot when i worked for the government but but the most important one for this conversation is the right of the patient to have access to all of the data that
18:06is generated about them and in the case of of children that right belongs to a parent
18:12to be able to collect all of the data and it’s so much broader than people realize it’s it’s all
18:18data in medical records and any data that exists in another system that’s used to make decisions
18:24about individuals so so so jake mentioned the difficulty of getting eeg tracings they’re
18:30part of the designated record set which is what patients have a right to access the problem is that a lot of times organizations didn’t realize that that was part of their right of access or
18:42they tried to discourage patients by saying we don’t have a way to get these to you these files are really large so so you know you have to be you have to be able to kind of break through some of
18:51that clue genius and i’m convinced that this is probably why i got hired to help start citizen in
18:57the first place is because i you know i i did have the advantage of knowing those regs like the back of my hand having worked in that organization and being able to say to healthcare systems
19:07that turned us down or made things hard for us to get records for you nope that’s not you can’t do
19:12that and here’s the piece of guidance that says that you can’t and you know slowly but surely
19:18kind of amassing a track record of being able to cut through some of that noise we we have not been
19:25uh we we don’t have that kind of machinery set up to do that in other countries yet and
19:30so there’s a little too much dependency for us on patients sourcing their own records but we
19:36do hope that that will change because again the law the law is on the patient side here
19:41yeah but but it still doesn’t mean you still don’t have to take a pickaxe to some of that you know some of that rock that stands in your way which is it’s unfortunate which Moral Imperative
19:52and if we have time we might come back to the the ways in which you have thrown a pickaxe at some problems and i think made the whole us healthcare system better for it but i wanna i wanna so we’ve
20:02shifted from defining the barriers to talking about how important they are Charlene said moral imperative Devin devin reminded us that if the patients have right to this data and what i really
20:12like that you said devin that i want to underline is doesn’t matter which legal system you’re in
20:17most of these rules and regs do have that premise the patient has an access to their data and those first principles are great for people like me who aren’t lawyers and when someone’s like well
20:26in Germany blah blah blah or where then pick a country blah blah blah i can just be like look do they or do they not have a right to their own data and if the answer is yes then let’s let’s
20:34figure out how to execute that i think that’s a important point but then before we before we go to that next slide I just want to come back to jake and and talk about one of the things one
20:44of the reasons i invited you here jake is is because what your company is doing is i think
20:52making possible through technology um the creation of something that is critical which is endpoints
21:00out of data right and and i think but you can’t do that if you can’t get your hands on the data so
21:07can you just double click on like why this is so important that we figure out a way i think devin’s
21:15pickaxe is a beautiful answer right so here’s jake with beacon biosignals here’s a bunch of parents
21:20who have kids who’ve had countless eegs and to be clear just to editorialize for a hot minute
21:26getting a kid with a rare neurological disease an eeg is a non-trivial experience you go to
21:31the hospital you put them in front of screens clinicians come in things are taped to their heads bandages are put on their heads they either wear a backpack or you’re walking around with a
21:39video camera and then for 4 6 8 28 48 72 hours this poor child has stuff stuck to their head
21:46while this precious data is gathered and you know blood sweat and tears all happen in this process
21:53blood hopefully not but occasionally and then it sits on a shelf and a computer and then jake meets family and says i want to make end points for your disease
22:02in partnership with pick a company and they’re like how do i get the ed eeg tracings and what so i don’t wanna i don’t want to talk for you jake but can you just
22:12double click on like the speed that’s possible if we could just connect the data yeah with youQuantitative Data
22:20yeah and it’s like you mentioned that we’ll see a lot firsthand getting this is an unbelievable burden on patients and their families and that when in these clinical
22:30settings you’re able to get all this data what a shame that it’s only you know one interpretation
22:36uh by one clinician and then that data is buried within these silos and makes it not accessible
22:41for the types of work that we’re doing so to to go into what you’re saying basically what we think is
22:47that we need more rigorous quantitative precision measurements for these new next generation
22:54precision therapies and so for us in our data modality looking at brain activity is a great
23:02way of understanding how a novel treatment is affecting the brain so currently
23:08we don’t really have the tools to efficiently do this and so oftentimes we use surrogates in clinical trials like the seizure diary where you know parents
23:19are given this additional burden to have to count you know what they see you know by eye as clinical
23:26events which of course is a extremely meaningful uh end point for the patient and the parents
23:35that’s something that again is not an equitable end point a lot of times parents aren’t able to always be at home watching their parents they’re watching their their children and then it of
23:45course is not capturing the subclinical activity in the brain there’s a lot going on that isn’t
23:50seen by by an observer whether that’s a parent or an epileptologist can’t just look at the patient
23:56and so for us we think that there’s a really interesting opportunity to at least supplement
24:02these endpoints so you have more shots on goal when you create a new precision therapy to see oh
24:08no even at this early stage trial in a small small end we can see that this new treatment is actually
24:16affecting brain activity something like the epileptiform spikes or seizures these quantitative
24:22you know pathologic events we can now rapidly capture these automatically more reliably than any
24:28epileptologist with our tools and we can do this almost instantaneously when we have the data
24:34and so this is the type of possibilities we open up when you have quantitative tools that have been validated to actually interrogate this data more shots on goal more if you can get it more shots
24:46on goal for treatments to hopefully advance to the next phase yeah i mean i just want to jump in and
24:52jacob i think this is so important because you know at the end of the day why are we trying to put together all this data it’s so that we can get therapies and cures for our kids and yeah the the
25:03point that you’re making around you know EEGs and endpoints really hits home for me so my daughter
25:09has a rare neurodevelopmental disorder and for you know for this i guess class of disorders seizures
25:18as counting seizures is typically you know the primary endpoint and this is really problematic
25:25for you know the broader set of neurodevelopmental disorders where you know a lot of kids you know
25:31for instance in STXBP1 have variable seizure profiles over their lifetime and you know in
25:37the case of my daughter she doesn’t have seizures but she has you know a spectrum of other you know
25:43symptoms and so being able to you know equip ourselves with you know the data that has been
25:51generated you know i was laughing when mike was talking about the EEGs because i barely survived
25:58my daughter’s last 24-hour EEG but you know we’ve never seen that data um and so being able to mine
26:08that you know so that we can have endpoints that can be successful across our spectrum of patients
26:16is so critical for us to be able to achieve getting these therapies to them
26:22yep yep okay i wanna um you all lead very innovative organizations devon What would happen if you didnt exist
26:29with citizen jake with beacon charlene with rare x actually and STXBP1 i would i would
26:35dare say STXBP1 as a leader in the rare disease space someone i copy as often as i can
26:43and when you’re dealing at the cutting edge and you’re innovating like this it’s easy to forget
26:48what would happen if you didn’t exist right if people weren’t working on these cutting edge scenarios what would happen so i think can we just take a second and paint a picture of what
26:59patients researchers and companies would do if if your organization and your and the peer group
27:05right if these solutions that we’re talking about that address these barriers didn’t exist
27:11let’s just quickly go around and remind people what we’d be up against so devin
27:16what did what did it look like before before citizen and it’s ilk
27:22well i mean i can’t imagine where we would be without the sort of the organizations that you
27:27all started because honestly you you are the ones who sort of pushed us it was is really
27:33family members we were founded by a family of of someone who who who died too young uh of a
27:40disease that should have been caught earlier and you know my colleague nasha fitter from FOXG1
27:47similarly like you all push us to do the things you know to to sort of put the ideas we have in
27:53our head and direct them into the right space so i will say that i i feel like our maybe one of the
28:00biggest value adds that we put into this mix is the data gathering is the you know what you you
28:08should not have to depend on on you shouldn’t have to do this yourself you shouldn’t have to depend
28:14on a research company doing it for you because it’s actually so hard to do that maybe some of them would would only be interested in studying your disease if you came to them with the data
28:24already or let’s say you had a partnership with someone who gathered a bunch of data and then they
28:29changed their minds or they lost their funding and rather than giving you back the data that you
28:35helped them gather or that was about you no it just disappeared it went on a shelf or it never got extracted in the first place um and then of course there’s the issue of you know once you get
28:45reams and reams of data how do you how do you make sense of that data right and it’s another piece of innovation that layers on top of all of this but i but i sort of feel like if we you know it’s really
28:54the the groups the patient advocacy organizations many of them led by parents that that kind of
29:01push the folks who think they’ve got a big idea or a good idea into sort of pursuing something
29:07that’s actually going to be meaningful for people yep yep and so without and without What would happen without Citizen
29:14but without citizen then you just just push on it a tiny bit you know you’re like what would happen
29:20it would be basically researchers reaching out to parents parents reaching out to the clinician sending the files to the researcher who hopefully has time and money to get through them
29:29and may or may not choose to share them i mean i will tell you being in citizen there’s one researcher a number of our families have gone to and he promptly
29:37takes lots of tests and readings makes you sign a consent you’re there with a doctor you’re trying to help your kid you sign the consent all these tests they go on a shelf fast forward two years
29:46i go to citizen citizen collects my son’s data from him and i say hey what about those all those EEGs and this and that he’s like oh no that was research that’s different i
29:54don’t have to share that because that was a research study and it just kills me i’m like i flew my son two time zones and subjected him to this and you won’t even share the data it’s
30:07but with citizen you know we we get all the other testing that tony’s had over his life and we’re able to share it again and again with researchers and companies can license it
30:17yeah that’s right with it without having this sort of silo that that we spoke to before and it’s it’s
30:23really the data access issue that jake brought up right from from the get-go as did as did Charlene
30:28right if you can’t access this data you are nowhere and yet it’s getting generated every day
30:35either in clinical encounters or in things that that parents and family members see and carrying caring for someone at home right and then jake you know without without by beacon What would happen without Beacon
30:45biosignals and actually being able to look at the tracings can you just take us back into a hospital
30:5310 15 20 years ago like kid has EEG what happens to that EEG how is that how is that those hours
31:01and hours of you know god knows how many electro data points processed and shared
31:07well i don’t i don’t think we even need to go back 15 or 20 years again what i what i had witnessed
31:13you know recently right now when we actually are able to get an eg in a clinical setting
31:20sometimes it can be a long eg um there is you know an epileptologist so somebody that’s gone through
31:28um in medical school neurology residency training and specialization fellowship and you know
31:34epilepsy that has to sit and read this entire EEG recording often with a long backlog on a given day
31:43and really has a hard time when being able to actually review an entire say 72 hour EEG so you
31:50can never actually look at all the data in all the different ways that you might want to let’s say if it were much shorter so you’re limited by a human having to go through these very long records
32:00second there is you know profound uh evidence showing the amount of inter-rater disagreement
32:08on uh epileptologists so that to be specific you see a given event and you know one epileptologist
32:17may say this is normal and another one may say that this is abnormal in fact there’s evidence that if you show the same data to the same epileptologist either later in time they may
32:26disagree with themselves and so before you know beacon you know you really have to rely on sort
32:34of reports of what a what a single epileptologist might review for a given file some of our you know
32:40biopharma partners before beacon would have to ask you know an epileptologist just to look at five minutes of the 60 minutes of data you know just we know it’s too much data for you to look
32:50at so just look at this small subset even though we know this is not capturing the full breadth of the data and the disease so you know we just unlock this opportunity to be
32:59able to actually assess all of the data and quantitatively and you can do it today tomorrow and two years from now it’s going to give you the exact same result and i think that’s how you build
33:08quantitative end points that actually move the needle right if you can get the dataWhat would happen without RareX
33:15and then uh charlene without rare can you can you just elaborate on the data silos and and
33:23what it what it what it would take without rare x and the ability to do what you’re doing yeah
33:30maybe i can start by talking about you know what were the critical challenges that we saw
33:35um in terms of you know trying to address with rare x and you know clearly data silos we’ve been talking about that a lot um and you know related to data lack of usable data
33:48lack of data and patient empowerment challenges and so um moving to lack of usable data um
33:56you know what we’ve seen is that studies might not include key data that’s actually the key data
34:02to drive drug development forward and information might not be collected um information might not
34:10be collected using data standards and so this complicates downstream analysis in rare disease
34:17we also have this big challenge that data often doesn’t exist so if you’re a new or emerging um
34:24community um you need to start collecting data and how do you start collecting it if you don’t have
34:30any baseline data so what do you measure and you know what do you collect and then finally
34:36um you know we’ve been i i really love that we’ve been talking about patients so much during this
34:42panel because i feel that the one of the most important challenges that rare x was started to
34:49address was that patients aren’t empowered to make decisions on the data they’re contributing and so then maybe i can flip and answer your kind of question which is what’s a world without rare
35:00x and our like-minded contemporaries um well first the traditional consent um where you know
35:09participants are consenting for data and it’s limited to the current study and there isn’t any downstream use i mean you just talked about that with the um with your example
35:20of um uh of tony going to a researcher and you know data isn’t produced in a way
35:28data would not be produced in a way that it would be openly available for researchers for all researchers and also in a research ready format um much more limited data would
35:40be available for rare disease especially for emerging and ultra-rare disorders and finally
35:47patients would have a much more limited role in deciding how their data can be used for research
35:55yep it’s all true i am i um i sent a newsletter out to my group and i always sign it time is brain
36:03because i want to remind people that we all love someone whose child uh is is has a brain that is being built badly right now because of some
36:11identified genetic deficiency and the sooner we get these precision therapies which jake mentioned
36:17um the sooner we can rectify that so moving fast and being efficient is so is so key anyone want to
36:24say anything before i go to the next question okay so we’ve we’ve talked about what we’re doing we’ve Whats next for RareX
36:31talked about what the barriers are we’ve talked about what the world would look like without us so hopefully now we know with citizen we can get the data fast hopefully we’ll figure out the eeg
36:40tracing jake can find the endpoints charlene and rarex can gather all that data working with rare
36:46disease groups like stxbb1 and syngap1 very exciting what’s what’s around the corner so
36:57as you as you think about data sharing and you’re sitting where you sit doing the work you do i’m curious when you look around the corner what what what what you get excited about
37:05being possible like it’s really it’s important to focus on the barriers and break them down but it’s also exciting to assume success and say okay what’s next i that’s that’s where i get going
37:16so jake let me let me start with you what’s possible give us some give us some good news
37:23yes i think we have great news i think that you know with with groups like that of our panelists
37:30we can do things like shrink the time that we do natural history studies and drug development right now again for everyone this is oftentimes we will do a
37:40one or two year long study you know either retrospective or identify patients where we
37:45need to better understand the disease because it was too hard to obtain the data on these patients in the first place so that we can now inform our studies when we start giving treatment
37:55with you know advances in data sharing we can grab all that data or work with beacon in our database
38:02and identify the biomarkers of interest you know in weeks not years and so now we’ve you know
38:08de-risk components of new novel clinical trials so that you can move forward much much faster
38:13so i think that’s that’s what really makes it exciting for us to start and then we can compare you know when we do start a clinical trial
38:21how you know these you know 10 or 12 patients in a phase one how do they compare to you know the
38:27patients in this larger group that we’ve collected across the country or the world to make sure this is really representative of the disease that we’re trying to study and that when we make a treatment
38:36it’s really going to impact you know patients all over and not just these particular individuals
38:43very cool so we can move faster time is brain and i think you can yeah i’m really excited here we go What do you get excited about
38:50charlene what what what do you get excited about when you look to the future i’m excited about
38:55what jacob talked about um i mean that is you know what we really want to shrink that time from years
39:02to weeks and that is tremendously exciting from a rare disease patient perspective um you know
39:09something else that i think bringing all of this data together and breaking down this silos enables
39:15is looking at diseases cross disorder so um you know with with rex that’s one of the things that
39:22we’ve really you know um architected the platform to do is to analyze to gather data in a structured
39:29and consistent way across disorders and so we’re really excited about this idea to not only
39:36enable analysis within a disorder but also for disorders where their shared symptomology
39:42or shared pathways to be able to analyze those disorders together and potentially come up with therapeutic strategies that can address a number of disorders instead of just a single one What are the new endpoints for trials
39:55yeah i i i’ve already started to see this with with your i mean this is sdxbp1 and syngap1 when
40:01when we share some data sets when i see one of which is citizen when i see side-by-side analysis
40:06of our kids i actually know okay your kids have more motor issues than my kids my kids have more
40:11aggression than your kids gi et cetera et cetera it’s utterly fascinating and if you think about the doctors like jake back when he was in the hospital they actually have a reference point
40:20they’ve seen five singap kids but they’ve never seen an stxr they could reference this research and get a sense okay these are the things i need to look at it’s so exciting and then devin when
40:31you look at the sorry go ahead jake i was just going to add one more thing to that because i think it’s such an important point not only are the other features of disease that may be similar
40:40and when you think about from our perspective and more broadly you know what are the new endpoints for trials that really we can build a community across you know rare disease organizations to
40:50say hey this quantitative seizure metric or quantitative epileptiform spike burden this is
40:55not just important for this one disease but we’re going to come together as a community that we know mike and myself and many others are thinking about really how do we go to the regulators and really
41:05move the whole field forward because this is not something specific to one niche disease we’re seeing this across the spectrum and think that we can move the whole field forward and that type of
41:13amazing work you know the rarics and others are doing allows these opportunities so we can do this
41:19yes yes yes because i think you know it’s important to know while there’s only a handful of The future of rare disease research
41:28amazing rare disease groups like the one charlene’s leads there’s hundreds of rare diseases and growing and as and as we and people are easy oh there’s 200 patients here three oh rare disease
41:37is so small it’s not it’s a huge cohort of kids who are suffering and if we can process that data
41:42at scale we can help them all which is important it’s more again it’s it’s a moral impairment but
41:48devin um what what do you get excited about as you look to the future um so uh in on on
41:56the theme of go faster be more efficient get there more quickly um this is also more of a us-based um
42:05uh advancement but i’m pretty excited about it so so one of the things that still slows us down
42:11uh at citizen is that it takes us it can take us up to 30 days um and potentially sometimes longer
42:18to gather all of uh one of our users information from all the places where they’ve been seen
42:25and then we are we have to have the parent or the patient themselves it’s an adult tell
42:31us when they’ve been seen again so that we can go back and collect any new records so there’s there’s it it doesn’t look very silicon valley right there’s a lot of sort of manual effort
42:42involved it takes a lot of time and and and there’s there are some policy developments in
42:47the us that are going to make it it should make it easier for patients to get data in a way that
42:53does that that gets them at least a solid set of data quickly within even you know 24 hours or less
43:02and the amount of data that is is sort of going through that very fast pathway is expanding
43:08so the idea of sort of driving this through the patient i think for a lot of companies it looked
43:14daunting because of the work involved in gathering the data in the first place and so some of these
43:21innovations around getting getting data quicker i think are going to be quite brown groundbreaking
43:28um now in rare again where some of the data that we’re trying to get is for example eeg tracings
43:34and other data that might not is not going to be on the short list of data that’s going to be
43:40available quickly there’s still going to be effort involved but if i can get most of the data that i
43:45need for our users in 24 hours and then i’ve got to spend you know to use the time of my people who
43:51who are who collect records to to to to chase down the hard stuff that allows us to scale
43:58that allows us to scale much more quickly that allows us to put data in the hands of researchers much more quickly takes some of the burden off of the parents to you know let us know when that when
44:08they’re when their child has been seen again so we can go back and collect the records there there’s some more opportunities for automatic refresh so i’m i’m i’m actually pretty excited about data
44:19access only getting better and quicker from here at least in the us and then hopefully the us will serve as an example for where other countries need to go and i i also would say you know some
44:30of the fda guidances around how they will consider real world data and real world evidence is pretty
44:36critical to the rare disease space i think the the the sort of orphan drug and vote and other
44:43departments at the fda that work in in rare sort of understand that what they’ve got is something
44:48different and requires more attention to be paid to real world data as opposed to reliant on you
44:55know the sort of pristine clinical trial data but that’s another sort of development that came out of the 21st century cures act that is that’s appears to be making a difference and is again
45:06another place where it’s quite possible that the u.s may be ahead of other countries uh in terms of
45:14you know leveraging data generated in clinical and home settings to power with drug discovery
45:27mike i think you’re on mute wow this shouldn’t be a our webinar there should be like a day-long session okay so
45:35there’s so much here that you just explained and i’m just gonna kind of try to synthesize how i
45:41explain what citizen does right you the parent consent citizen collects all your records in 30 days and devon you just said that’s too long and it’s too much work it’s as a parent it feels like
45:50light speed and it’s great that you guys are doing the work right um but then after 30 days that data
45:55has to be processed and then it’s made available to researchers and clinicians and then that’s used
46:01like cuckoo clock is going off in the background and then that’s used to create real world evidence right it’s important to just spell it out for people because people don’t people think these
46:09terms are interchangeable right and and you’re i suspect you’re being a little modest i mean you say maybe the u.s is ahead i mean you you basically managed hipaa for years right
46:17so you you’ve been in the trenches of this of how it’s how it’s working and it’s important to remind people that there’s that pathway and what i heard you say was that collection effort that took
46:2830 days now that we figured it out we cannot we’re learning how to use robots to do it and there’s a
46:34regulatory environment that permits that right so we got the rules in place and the robots in place to make that happen and then you layer on rare x which would allow these different data things
46:43to connect and then hopefully now the trouble is those pipes are built for medical records
46:48and then one of the one of the obvious little obvious why i invited jake to be here but one of the troubles is that eegs don’t flow neatly through those pipes right that’s a big ugly data
46:59set that lives in different computers and we need to think about that and i and i will throw in that you know whole exome and whole genome sequencing also does not fit neatly through those pipes right
47:10people get whole excellent sequencing this massive amount of data and they get told you have one one snip and this is your cause of disease but the truth is as as compute and research evolves to the
47:20point where we could actually process that data we’re going to have the same problem how do we get these massive files that are that are different based on the version and the company and the
47:30heart of so many reasons they’re different aren’t interoperable and how do we get them to the place where they can be used to facilitate precision therapies it’s it’s really it’s it’s really
47:39exciting and important and um i i just i’m so glad that we have had this time all right i need Alignment of incentives
47:45to take questions or i’ll get in trouble i get i don’t get in trouble so let’s let’s take questions for the audience um but before i do charlene jake devin any thoughts you want to make before
47:56we open it up because the questions could take us in new directions charlene last last thought
48:01or go to question i just wanted to bring something up that we touched on earlier but didn’t really
48:06um kind of talk much about which is alignment of incentives in research and yeah i think that this
48:14is really important because it’s an issue that we still have to tackle and you know obviously as as discussed on today’s panel there’s a lot of work that’s happened in terms of changing
48:24many aspects and many processes around um you know access to data and you know and um utilizing it
48:31for research but research incentives are still a huge challenge you know in academia publisher
48:38parish is still you know kind of the the dominant um approach and so researchers i don’t think that
48:45you know many intend to or would even think that they’re hoarding data but because they need to
48:51write their paper before allowing others to access the data that becomes a challenge because that
48:56delays access you know to the data um and then the other thing on the um commercial side with pharma
49:05is that i think that pharma are starting to understand that having natural history data
49:10is not a competitive advantage unto itself like pharma is going to differentiate and win based on
49:16their technology and their ability to move their pipeline forward um but we need a way to transform
49:23um you know the current way that research is being done and initiated and make it easy
49:30for pharma to collaborate in a pre-competitive way on shared data sets and um you know i’ll just say
49:36that i think that public private partnerships are a way to establish and scale this model very nice Next steps
49:46jake closing thought before i go to questions
49:53muted i think you’re muted jake
50:00i was just going to uh sort of double click on that as i think that was even more eloquently stated than i would have so i think that’s those are
50:08the next steps that hopefully will enable these the future that we all want quickly
50:13pre-competitive natural history studies and addressing the the conflicts the inherent conflicts of interest in the way academia is structured in the sense of emergency the specifics
50:23on the academia side you know one of the things that we’re trying to do is again for us we’re not motivated by publications only um because we’re trying to accelerate novel therapies so we’re
50:33experimenting what happens if we give our tools you know for free to some of these academic groups
50:38that give them super powers to be able to analyze their data using some of beacon’s tools and now they can publish papers on you know which is their currency for advancing their careers but now we
50:49can use some of this data to better understand the disease and build better biomarkers but yeah like
50:54you guys like we’ve talked about this requires creativity to be able to you know work within the
51:00existing structures as opposed to thinking about how to break them down yeah last thought devin
51:07no i mean i couldn’t agree more i’m uh it’s i feel like we’ve surfaced a lot of really good
51:14stuff on this call and i’m i’m i’m excited to work with everyone on this because we’re
51:20again oh we just want to be we just want to give you the data that’ll power what you need
51:26so that’s that’s our kind of niche role in this whole equation so i would love you to do it
51:38that would be amazing all right i got to take some questions
51:44um so a few questions have rolled in i will if you’re looking at the chat i’ll start at Questions
51:49the i’ll start with number one and i’ll i’ll work my way up so i’m at the bottom what strategies are used to address european privacy challenges changes in view of covet impact
52:00i mean i could have stopped it european privacy challenges before i even said covet but let’s make
52:06that two questions any thoughts on european data regs and and sort of a european approach to data
52:11privacy versus what we what we’re what we’ve really focused on here which is the u.s one and then has covitt had an impact on data sharing and collaboration anyone
52:23well i i you know so i can take a stab at the first stab at a couple of both of those actually
52:29so um you know again everyone sort of looks at gdpr european privacy regimes as oh you know
52:37they are more astringent than what’s going on in the u.s and again the fact of the matter is is
52:43that they are have you know patient consent plays a very strong role in provisioning access to data
52:51and patients have strong rights in their data including the right to get a copy of it so in
52:56many respects the the the gdpr so-called obstacles actually play very well in sort of patient and
53:05family driven models of data gathering and collection it i i just i just think it’s been underutilized as a tool over there because it’s less familiar than maybe it is over here um
53:19and then in terms of covet 19 and we we did see an amazing dedication of resources across
53:26the globally really toward fighting the pandemic it’s like you know we all had a common foe
53:33all of a sudden and some of the silos around data sharing um melted away i mean it’s not like we
53:40didn’t struggle to gather data especially even here in the u.s in a timely way but but i saw
53:47lots and lots of collaborations scientific collaborations uh for-profit organizations
53:53creating databases that they basically you know the data broker saying we’re opening up our data
53:59for free for covid researchers to come and take a look at it and and to do studies on it and at
54:05no charge and you know that kind of a kind of all hands on deck approach is absolutely amazing
54:12and it does make you wonder why we can’t deploy that more toward you know diseases that are not
54:18epidemic or pandemic but are you know really ones that we’re still struggling with and that for the
54:26families involved are are as bad if not worse than what we’ve been going through with covid
54:34jake charlene thoughts on europe or kovid
54:40i’ll just say that um we have to be able to be global because rare disease patients are all over the world and so
54:51this is a critical thing for us to figure out in terms of being able to um really bring together these cohorts of patients across country borders yep
55:02okay keep going i mean i will only say that in addition to the regulatory environment which which
55:07um devin has pointed out is more maybe more the same than different there is the cultural approach right there is i have i have talked people a lot of nationalities into signing up for citizen
55:17and um that you’ve got a there’s a different conversation around privacy with different nationalities and it’s that’s that can’t be missed yeah we had a question what is
55:25your experience sorry i said for sure yeah and and having our platform available in different
55:31languages would sure help too yeah we’ll get there hopefully with translation then Patient Advocacy Groups
55:37it’s all software what is your experience collaborating with patient advocacy groups so i quickly go through that because i think we’ve talked a little bit about it but
55:46charlene do you work with patient advocacy groups yeah in fact we on board disease communities by
55:54collaborating with um patient advocacy groups and so we feel that that’s really important because
56:00you know at the end of the day the trust is within the community and you know so we want to work with
56:06the you know that group to enable that group to be successful with you know onboarding and
56:12initiating data collection so if somebody wants to work with you they should just call you up If somebody wants to work with you
56:18yes absolutely great devin same question yeah i was going to say ditto we wouldn’t be where we are without patient advocacy groups we depend
56:29on them to help us recruit people to the platform we wouldn’t we probably wouldn’t really have
56:35a way to function without an advocacy group at the other end you know as a as a startup for so long
56:42we only got acquired towards the end of last year like we we were limited by our bandwidth
56:47in terms of the number of advocacy groups that we would support but i uh you know again on the horizon see us being able to scare scale more quickly to more groups and
56:58more diseases in uh in the very near future um with the additional resources of a larger company
57:05plus the ability to sort of combine the genetic and phenotypic data from the can’t wait okayWhat are your plans for the future
57:15yeah we’re as a very very early stage startup you know we’re just sort of getting getting getting
57:21started ourselves we’ve obviously been in our conversations with mike and we’ve had groups approach ours which we we want to support um going forward we definitely you know in
57:32the indications where we’re going after first you know i think the patient advocacy groups
57:37and beacon are you know 100 aligned and we want to understand the data as quickly
57:42as possible and often going through the academic medical centers and otherwise um can be very difficult and encumbering so you know with mike and syngap1
57:55for example we’re talking about how to think about you know getting large amounts of data so that we can do these types of studies really quickly and bring that information to the world to be able
58:03to you know have actionable insights so i think that for us over the next few years i can imagine
58:08we’ll have you know very strong relationships as we grow our company and support our capabilities to go go after a number of these rare neurologic disorders okay one and a half more questions
58:19because i think the last one i’m just going to try to take what degree of this one’s this one’s What degree of clinical lab data is required or necessary
58:24this one’s interesting what degree of clinical lab data and ehr standardization is required
58:32or necessary i guess to understand strength of evidence for regulatory decision support
58:38that’s a that’s a do we do everything have to be standardized or we can’t use it or not charlene devin well maybe i can take a first um stab at this so um you know we feel that data
58:52standardization is really important so mapping you know data to um you know standards whether they be
58:59hpo or hl7 and you know i know that citizen also you know does a similar thing um and there
59:06is fda guidance um you know for uh that i think it’s draft guidance that’s come out
59:13on real world data the of the necessity of mapping to standards and so this is a
59:19really important aspect of building a data set that can be used um you know for you know both
59:26generating evidence and then you know also moving forward to support regulatory decision support
59:34yeah you know when the data are already standardized in the electronic record and coming from the labs it makes our job so much easier
59:45but we’ve certainly found that there’s just a mother load of data in non-standard non-structured
59:51formats um a lot of it in clinical notes for example progress notes are are almost like
59:59the gold mine for understanding what’s happening with a patient in addition of course to to to labs
1:00:06in the case of of um neurological diseases eeg tracings all of that stuff complete the whole
1:00:12picture you’ve got to have the ability to sort of take the non-structured data and standardize it
1:00:18you know if there are standards available and and you know again that’s something that that we have
1:00:24really worked on since the very beginning and continue to improve our capacity to do that
1:00:30so now in terms of sort of how the fda feels about non-structured data i mean i think if
1:00:37they can um understand the origin of the data feel comfortable in the provenance of the data points
1:00:45that are coming before them they have a a a decent enough size data set um i mean that’s supposed to
1:00:52be the whole point of gathering real world data that turns into real world evidence that supports
1:01:00clinical and regulatory and research decision making so it the fda is just at least in the u.s
1:01:07again just starting to i think place more reliance on real world evidence versus requiring the sort
1:01:14of pristine standardized collection as part of like through a clinical trial um and so i i think the next couple of years will be very telling in terms of just how willing the
1:01:25regulatory agency is is in accepting some of this data that comes out of non-traditional sources
1:01:32jake any thoughts on this question about standardization i for example does an amazing job
1:01:40being able to organize even though this sort of additional uh clinical real world data may come
1:01:48in different formats being able to think about how what is common across these different data types so that you can then build models to better understand what is being seen in the real world
1:01:58of course you know that type of control isn’t always there but that is supporting evidence as you’re building out you know these natural history studies for example uh can be critically
1:02:07valuable to making you know decisions about go no go to make this new therapy yeah
1:02:14so the last question is and then i’ll give it back because i realize we’re at time what is the best platform slash database if you’re starting from scratch so if you’re a
1:02:20brand new rare disease group whatever i mean i’m gonna editorialize here my answer is on the screen right call citizen get on the list call charlene sign up for rare ex call call jake get on his
1:02:31dance card like if you’re starting from scratch when i was asked to host this i called the three best people i knew and they’re on the screen right now but until you get on their dance cards
1:02:42my advice to every rare disease group is make sure you know your patience do not do not delegate this
1:02:47to a well-meaning researcher with a little bit of funding because they’re going to fund a natural register for two years and they’re going to go to another institution and you will be precluded from
1:02:55seeing that data by some irb that is attempting to protect the patients makes me bananas so my answer
1:03:01is get to know your community keep a contact list and find professional partners because
1:03:07as you saw today this is highly complicated and you need people who really think about it all day
1:03:12long that’s that’s i’m that’s my thought would anyone amend that before i hand it back to tom
1:03:20no i totally agree build your community first spend your time getting to know your people
1:03:26because it would be it’s it’s a dependency that can’t be skipped over so we’re here
1:03:34and with that before i give it to you tom i just want to say thank you to the panelists and thank you to bayer rossi for for inviting me to do this i really this is a this is a
1:03:42talk i’m going to forward to a lot of people and strongly urge them to listen to over to you tom
1:03:49brilliant thank you very much mike and thanks to you all for sharing these great insights and being really generous with your time today on behalf
1:03:56of bayerasi and marcus evans webinars we’d just like to thank you all for joining us and do hope you’ll be listening in at our next event take care and have a good rest of your day


